Related Experiment Video
Updated: Jan 27, 2026

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus
Published on: January 17, 2025
Preventing lung pathology and mortality in rabbit Staphylococcus aureus pneumonia models with cytotoxin-neutralizing
Lukas Stulik1, Harald Rouha2, Delphine Labrousse3
1Arsanis Biosciences, Vienna, Austria. lukas.stulik@arsanis.com.
Abstract:
Staphylococcus aureus pneumonia is associated with high mortality irrespective of antibiotic susceptibility. Both MRSA and MSSA strains produce powerful cytotoxins: alpha-hemolysin(Hla) and up to five leukocidins - LukSF-PV, HlgAB, HlgCB, LukED and LukGH (LukAB) - to evade host innate defense mechanisms. Neutralizing cytotoxins has been shown to provide survival benefit in rabbit S. aureus pneumonia models. We studied the mechanisms of protection of ASN100, a combination of two human monoclonal antibodies (mAbs), ASN-1 and ASN-2, that together neutralize Hla and the five leukocidins, in rabbit MRSA and MSSA pneumonia models. Upon prophylactic passive immunization, ASN100 displayed dose-dependent increase in survival and was fully protective against all S. aureus strains tested at 5 or 20 mg/kg doses. Macroscopic and microscopic lung pathology, edema rate, and bacterial burden were evaluated 12 hours post infection and reduced by ASN100. Pharmacokinetic analysis of ASN100 in bronchoalveolar-lavage fluid from uninfected animals detected efficient penetration to lung epithelial lining fluid reaching peak levels between 24 and 48 hours post dosing that were comparable to the mAb concentration measured in serum. These data confirm that the ASN100 mAbs neutralize the powerful cytotoxins of S. aureus in the lung and prevent damage to the mucosal barrier and innate immune cells.
Insights
ASN100, a combination of two monoclonal antibodies, effectively neutralizes Staphylococcus aureus cytotoxins. This treatment significantly improves survival and reduces lung damage in pneumonia models, offering a promising therapeutic strategy.
Area of Science:
- Infectious Diseases
- Immunology
- Pulmonology
Background:
- Staphylococcus aureus pneumonia presents high mortality, independent of antibiotic resistance.
- Both MRSA and MSSA strains produce cytotoxins like alpha-hemolysin (Hla) and leukocidins, crucial for immune evasion.
- Previous studies indicate neutralizing these toxins can improve survival in pneumonia models.
Purpose of the Study:
- To evaluate the protective efficacy of ASN100, a dual monoclonal antibody therapy, against S. aureus pneumonia in rabbit models.
- To investigate the mechanism of ASN100's protection by assessing its impact on lung pathology and bacterial burden.
- To determine the pharmacokinetic profile of ASN100 in lung tissue.
Main Methods:
- Prophylactic passive immunization with ASN100 in rabbit models of MRSA and MSSA pneumonia.
- Assessment of survival rates, macroscopic and microscopic lung pathology, edema, and bacterial burden at 12 hours post-infection.
- Pharmacokinetic analysis of ASN100 in bronchoalveolar-lavage fluid and serum.
Main Results:
- ASN100 demonstrated dose-dependent increases in survival and provided full protection at 5 or 20 mg/kg against all tested S. aureus strains.
- Treatment with ASN100 significantly reduced lung pathology, edema, and bacterial burden.
- Efficient penetration of ASN100 into lung epithelial lining fluid was observed, with peak concentrations comparable to serum levels.
Conclusions:
- ASN100 effectively neutralizes key S. aureus cytotoxins in the lung.
- The antibody combination prevents damage to the mucosal barrier and innate immune cells, improving outcomes in pneumonia.
- ASN100 represents a potential therapeutic strategy for S. aureus pneumonia by targeting virulence factors.
Related Concept Videos
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
The Fluid Mosaic Model
Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Models of Health Promotion and Illness Prevention II
The agent-host-environment model states that disease results...
Fluid Mosaic Model
Models of Health Promotion and Illness Prevention I
The health belief model (HBM) attempts to predict health-related behavior in specific belief patterns. According to the HBM, a person's...

